Lead Sponsor

Ablynx, a Sanofi company

Age

18 - 64 years

Sex

ALL

Healthy Volunteers

No

•1. Man or woman ≥ 18 years and \< 65 years of age
•2. Have a diagnosis of SLE for at least 6 months prior to screening and fulfill the 1997 American College of Rheumatology (ACR) or 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria
•3. Have moderate to severe active SLE
•4. Have seropositive disease at screening
•5. Subject must be at least on one or more of the treatments for SLE as listed in the protocol
•6. Others as defined in the protocol

•1. Have an A score on the revised BILAG-2004 other than in the mucocutaneous and/or musculoskeletal system at screening and at baseline for the organ systems that can be clinically assessed
•2. Have a systemic inflammatory disease other than SLE
•3. Clinically significant infection treated or needing treatment
•4. Any active or recurrent viral infection that based on the Investigator´s clinical assessment makes the subject unsuitable for the study
•5. Have received prior therapy blocking the interleukin-6 (IL-6) pathway
•6. Others as defined in the protocol

Related studies

NCT07330245 · Lupus Erythematosus, Systemic

NCT07015983 · Lupus Erythematosus, Systemic, Lupus Nephritis

NCT07438496 · Lupus Erythematosus, Systemic

NCT06673043 · Lupus Erythematosus, Systemic

NCT05648500 · Lupus Erythematosus, Systemic

A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus